Table of Contents Categories
  • Noninfectious immunodeficiency-related cutaneous conditions
  • Predominantly antibody deficiencies
  • Syndromes affecting immunity
  • Syndromes with tumors
    •   Encyclosphere.org ENCYCLOREADER
      supported by EncyclosphereKSF

    Thymoma with immunodeficiency

    From Mdwiki - Reading time: 4 min
    Thymoma with immunodeficiency
    Other names: Good syndrome
    Individual with Good syndrome a) Computed tomography findings demonstrating mediastinal abnormality b) thymus gland specimen was stained with hematoxylin/eosin

    Thymoma with immunodeficiency (also known as "Good syndrome") is a rare disorder that occurs in adults in whom hypogammaglobulinemia, deficient cell-mediated immunity, and thymoma (usually benign) may develop almost simultaneously.[1]: 82 [2] Most reported cases are in Europe, though it occurs globally.[3]

    Dr. Robert Good was first to describe the association between thymoma and hypogammaglobulinemia in 1954.[4] Much remains to be understood about its pathogenesis.[5]

    Signs and symptoms[edit | edit source]

    Most patients present with an immunodeficient state and recurrent sinopulmonary infections in their 4th or 5th decade of life. The immunodeficiency may occur before or after the diagnosis of a thymoma.[4]

    Immunodeficiency involves both deficient humoral and cellular immunity. Patients have low total serum antibodies. The thymoma may inhibit the thymus’s normal role in production of self-tolerant T lymphocytes. These T-lymphocytes then attack the B cell precursors in the marrow, preventing maturation and ultimately resulting in hypogammaglobulinemia.

    Good Syndrome is associated with other autoimmune conditions including pure red cell aplasia[6] and myasthenia gravis.[4]

    Pathogenesis[edit | edit source]

    The cause of Good Syndrome is unknown. It is thought to be an autoimmune process affecting the bone marrow.[3]

    Diagnosis[edit | edit source]

    Definition[edit | edit source]

    There are no formal diagnostic criteria.[5] Generally it can be defined as an adult-onset primary immunodeficiency associated with thymoma, hypogammaglobulinemia, diminished B and T cells, and inverted CD4/CD8+ ratio.[2] It has been suggested that Good Syndrome is a subset of common variable immunodeficiency (CVID).[3]

    Treatment[edit | edit source]

    The mainstay of treatment consists of thymectomy and immunoglobulin replacement with intravenous immunoglobulin. Immunodeficiency does not resolve after thymectomy. Immunosuppression is sometimes used.[2]

    The Centers for Disease Control and Prevention recommend pneumococcal, meningococcal, and Hib vaccination in those with diminished humoral and cell-mediated immunity.

    Some have advocated prophylaxis with trimethoprim-sulfamethoxazole if CD4 counts are lower than 200 cells/mm^3, similar to HIV/AIDS patients.

    See also[edit | edit source]

    References[edit | edit source]

    1. ↑ James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: Clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
    2. ↑ 2.0 2.1 2.2 Miyakis, Spiros; Pefanis, Angelos; et al. (2006). "Thymoma with immunodeficiency (Good's syndrome): Review of the literature apropos three cases". Scandinavian Journal of Infectious Diseases. 38 (4): 314–320. doi:10.1080/00365540500372663. PMID 16718939. S2CID 44472631.
    3. ↑ 3.0 3.1 3.2 Kelesidis, Theodoros; Otto, Yang (2010). "Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence". Clinical Immunology. 135 (3): 347–363. doi:10.1016/j.clim.2010.01.006. PMC 8071094. PMID 20149753.
    4. ↑ 4.0 4.1 4.2 Kelleher, P; Misbah, S A (2003). "What is Good's syndrome? Immunological abnormalities in patients with thymoma". Journal of Clinical Pathology. 56 (1): 12–16. doi:10.1136/jcp.56.1.12. PMC 1769851. PMID 12499426.
    5. ↑ 5.0 5.1 Jansen, Anne; van Deuren, Marcel; et al. (2016). "Prognosis of Good syndrome: mortality and morbidity of thymoma associated immunodeficiency in perspective". Clinical Immunology. 171: 12–17. doi:10.1016/j.clim.2016.07.025. PMID 27497628. Archived from the original on 2022-03-25. Retrieved 2022-01-04. {{cite journal}}: More than one of |accessdate= and |access-date= specified (help); More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help)
    6. ↑ Hirokawa, Makoto; Sawada, Ken-ichi; et al. (January 2008). "Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group". Haematologica. 93 (1): 27–33. doi:10.3324/haematol.11655. PMID 18166782. Archived from the original on 2021-04-18. Retrieved 2022-01-04. {{cite journal}}: More than one of |accessdate= and |access-date= specified (help); More than one of |archivedate= and |archive-date= specified (help); More than one of |archiveurl= and |archive-url= specified (help)

    External links[edit | edit source]

    External resources
    This article is licensed under CC BY-SA 3.0.
    Original source: https://mdwiki.org/wiki/Thymoma with immunodeficiency
    Status: article is cached
    Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF